Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384045 | 0.90 | RXRA (0.57) | MAOBRXRARXRBRXRGL3MBTL1 | |
| SCHEMBL12939162 | 0.89 | MAPT (0.53) | MAOBRXRARXRBRXRGMAPT | |
| SCHEMBL12659914 | 0.89 | RXRA (0.53) | MAOBRXRARXRBRXRGMAPT | |
| SCHEMBL19326705 | 0.82 | MAOB (0.60) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12659913 | 0.82 | RXRA (0.58) | RXRARXRBRXRGMAPTCYP2C9 | |
| SCHEMBL6544788 | 0.82 | RXRA (0.53) | MAOBRXRARXRBRXRGMAPT | |
| SCHEMBL1036349 | 0.81 | MAPT (0.59) | MAOBRXRARXRBRXRGMAPT | |
| SCHEMBL4140081 | 0.81 | MAOB (0.67) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL6458759 | 0.81 | MAOB (0.58) | MAOBRXRAMAPTCYP2C9CYP2C19 | |
| SCHEMBL8908814 | 0.81 | RXRA (0.63) | MAOBRXRARXRBRXRGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | MAOB 677/4885RXRA 2115/4885RXRB 1531/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | MAOB 3748/4885RXRA 1090/4885RXRB 1491/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | MAOB 665/4885RXRA 2084/4885RXRB 1515/4885 |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3440/4885RXRA 110/4885RXRB 244/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3251/4885RXRA 115/4885RXRB 225/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3368/4885RXRA 112/4885RXRB 250/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3440/4885RXRA 110/4885RXRB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.